Read by QxMD icon Read

Future Cardiology

Colin M Barker, Michael J Reardon
Transcatheter aortic valve replacement has become an acceptable alternative to surgical aortic valve replacement in patients who are intermediate to high risk for surgery. The Lotus™ valve system (Boston Scientific, MA, USA) is an unique, mechanically expanded device. The system includes a braided nitinol frame and an adaptive seal to minimize paravalvular regurgitation. REPRISE III illustrated that among high-risk patients the use of the Lotus valve compared with a self-expanding valve did not result in inferior outcomes for the primary safety end point or the primary effectiveness end point...
August 24, 2018: Future Cardiology
Cameron T Lambert, Bruce L Wilkoff, Khaldoun G Tarakji
Cardiac implantable electronic devices (CIEDs) including pacemakers, implantable cardioverter defibrillators and loop recorders have become widespread adjuncts in the care of patients with cardiovascular disease. CIEDs provide increased diagnostic yield, better quality of life and improved longevity. While there are obvious benefits with these devices, the mere fact that these therapies involve implantation of a foreign device within the body leads to certain risks. The most feared complication associated with CIED use is infection...
July 31, 2018: Future Cardiology
Alice Le Huu, Dominique Shum-Tim
The intra-aortic balloon pump (IABP) is frequently used to support severely compromised ventricles in critically ill patients. Its relatively affordability and ease of insertion has cemented its position as the first line of treatment for hemodynamic support in cardiogenic shock. Accordingly, the current ACC/AHA recommendations maintain a Class 2A for the use of IABP in shock. However, a review of the current literature suggests that the evidence supporting the American College of Cardiology and American Heart Association (ACC/AHA) guidelines are equivocal...
July 2018: Future Cardiology
Giuseppe Limongelli, Karim Wahbi
No abstract text is available yet for this article.
July 2018: Future Cardiology
Romain Itier, Jerome Roncalli
Progress has been made into research on new therapies, mechanical and pharmacological approaches and repair/regenerative cellular therapy to treat irreversible cardiovascular pathologies, such as acute myocardial infarction. Research into cellular therapies is exploring the use of new cellular types. Although the therapeutic effects of cell therapy remain modest, results from clinical trials are encouraging. To expand this improvement, advances are being made that involve the paracrine function of stem cells, the use of growth factors, miRNA and new biomaterials...
July 2018: Future Cardiology
Majd B Protty, Simon J Wilkins, Hannah C Hoskins, Ban B Dawood, Jamie Hayes
AIM: Antiplatelets have been used for decades to prevent atherothrombotic disease, but there is limited 'real-life' prescribing data. We hereby report the prescribing patterns for oral antiplatelets in Wales, UK. METHODS/RESULTS: Retrospective analysis of anonymized data in Wales from 2005 to 2016 revealed differences in prescribing patterns of oral antiplatelets. Aspirin and dipyridamole use declined with a corresponding increase in clopidogrel prescription. Costs declined with a sharp decrease coinciding with clopidogrel coming off patent...
July 2018: Future Cardiology
Benjamin Viaris de Lesegno, Catherine Nelson-Piercy
No abstract text is available yet for this article.
July 2018: Future Cardiology
Mohammad Amin Shahrbaf, Mohammad Parsa Mahjoob, Isa Khaheshi, Mohammad Ali Akbarzadeh, Elham Barkhordari, Mohammadreza Naderian, Farbod Zahed Tajrishi
ST-elevation myocardial infarction (STEMI) is one of the potential causes of death worldwide. In spite of substantial advances in its diagnosis and treatment, STEMI is still considered as a major public health dilemma in developed and particularly developing countries. One of the triggering factors of STEMI is supposed to be air pollutants like gaseous pollutants including, sulfur dioxide, nitric dioxide, carbon monoxide, ozone and particulate matters (PM) including, PM under 2.5 µm (PM2.5 ) and PM under 10 µm (PM10 )...
July 2018: Future Cardiology
Stefanie Klenke, Sebastian Eul, Jürgen Peters, Till Neumann, Michael Adamzik, Ulrich H Frey
Ischemic cardiomyopathy (ICM) is characterized by accumulation of p53 causing apoptosis of cardiomyocytes and resulting in upregulation of miRNA (miR)-192, which plays an important role in the development of heart failure after acute myocardial infarction. However, for other cardiomyopathies, miR-192 seems to have minor relevance. We tested in a prospective, observational study comprising 91 patients with diagnosed heart failure (59.3% ICM and 40.7% non-ICM), the hypothesis that miR-192 expression predicts survival in patients with ICM...
July 2018: Future Cardiology
Mohamed Ali, Hatim Yagoub, Abdalla Ibrahim, Mohamed Ahmed, Munir Ibrahim, Jean Saunders, Alice Brennan, Donal Cahill, Terence Hennessy, Brian G Hynes, Samer Arnous, Thomas J Kiernan
AIM: The GuideLiner (GL) is a widely used catheter primarily in complex percutaneous coronary intervention (PCI). Deep seating of the GL and distal stent placement may be facilitated by the anchor-balloon technique (ABT). METHODS: We aimed to prospectively analyze procedural details, technical success, complications and in-hospital outcome in patients who underwent PCI using the GL catheter and the ABT. RESULTS: A total of 118 patients underwent PCI with the aid of the GL and ABT...
July 2018: Future Cardiology
Satya S Shreenivas, Dean J Kereiakes
The SYNERGY stent is composed of thin, platinum-chromium metal alloy struts and an ultrathin, bioabsorbable poly-DL-lactide-co-glycolide polymer limited to the abluminal strut surface which elutes everolimus prior to complete resorption within 3-4 months. SYNERGY was designed to reduce inflammation and facilitate stent healing compared with permanent polymer drug eluting stents. This review summarizes the preclinical and clinical development of SYNERGY, its integration into clinical practice and future directions...
July 2018: Future Cardiology
Emma Pascall, Robert Mr Tulloh
Pulmonary hypertension is defined as a mean pulmonary arterial pressure ≥25 mmHg. We focus on its relevance in congenital heart disease, reviewing pathophysiology, diagnosis and management. Pulmonary hypertension is a relatively common complication of congenital heart disease, with adult prevalence between 5 and 10%. A multifactorial cause is recognized, relating to the size and nature of cardiac defect as well as environmental and genetic factors. More complex disease is increasingly recognized rather than pure Eisenmenger complex...
July 2018: Future Cardiology
Manjiri Joshi, Robert M R Tulloh
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections and causes up to 200,000 infant deaths a year worldwide. The average rate of hospitalization for severe RSV infection is 5 per 1000 children, and the rate is three-times higher in those with congenital heart disease (CHD). Palivizumab, a monoclonal antibody, reduces hospitalization rates and intensive care admissions. It is used prophylactically and is administered as monthly doses during the RSV season. Hemodynamically unstable CHD is the most susceptible CHD to a severe episode of RSV infection...
June 7, 2018: Future Cardiology
Edelmira Martí, Alejandra Segado, Irene Pastor-Galán, Paula Amat, Maria José Remigia, Carlos Solano, Blanca Navarro
AIM: To analyze the clinical profile and rates of stroke, major bleeding and intracranial hemorrhage of patients with atrial fibrillation (AF) treated with rivaroxaban in clinical practice. METHODS: Retrospective study of AF patients anticoagulated with rivaroxaban in a Healthcare Area of Valencia, Spain. Patients started treatment with rivaroxaban from July 2012 to December 2015. RESULTS: A total of 230 patients (mean age 76.9 ± 9.9 years; CHA2 DS2 -VASc 4...
May 2018: Future Cardiology
Alejandro Isidoro Pérez Cabeza, José Antonio González Correa, Pedro Antonio Chinchurreta Capote, Rafael Bravo Marqués, Francisco Ruiz Mateas, Gabriel Rosas Cervantes, Fidel Mesa Prado, Sergio López Tejero, Almudena Valle Alberca
AIM: To evaluate medication persistence and outcomes in patients with atrial fibrillation after 2 years of treatment with rivaroxaban in routine practice. METHODS: Retrospective study of atrial fibrillation patients in whom rivaroxaban was prescribed during the first quarter of 2014 in the healthcare area of Costa del Sol (Málaga). RESULTS: A total of 111 patients (mean age 74.9 ± 10.9 years; 52.3% men; CHA2 DS2 -VASc 3.6 ± 1.3; HAS-BLED 1...
May 2018: Future Cardiology
Sara Muñiz Lobato, Carlos Tarrazo Tarrazo, Elena González Fernández, Marlén Morán Alcalá
AIM: To analyze the clinical profile and outcomes of patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital. METHODS: Retrospective study of patients with nonvalvular atrial fibrillation that started treatment with rivaroxaban between July 2013 and May 2017 in a regional hospital. RESULTS: 189 patients (age 76.0 ± 9.4 years; CHA2 DS2 -VASc 4.1 ± 1.7; HAS-BLED 2.1 ± 0.9) were included. Rivaroxaban 20 mg was taken by 74...
May 2018: Future Cardiology
Olga Gavín Sebastián, Macarena Izuzquiza Fernández, Raquel Martínez Fernández, Luis Palomera Bernal
AIM: To assess the clinical profile and thromboembolic and bleeding events in patients with nonvalvular atrial fibrillation (AF) who were attended in a hematology unit. METHODS: Retrospective study of AF patients that started treatment with rivaroxaban between February 2012 and June 2016 in a hematology unit from a tertiary hospital in Spain. RESULTS: Overall, 243 patients (mean age 78.4 ± 10.1 years; 47.5% women, CHA2 DS2 -VASc 3.7 ± 1...
May 2018: Future Cardiology
Juan José Cerezo-Manchado, Begoña Navarro-Almenzar, Ginés Elvira-Ruiz, Faustino García-Candel, Pedro José Flores-Blanco, Cesar Caro-Martínez, Sergio Manzano-Fernández, Natalia García-Iniesta, Javier Sánchez-García, Valentín Cabañas-Perianes, José María Moraleda-Jiménez
AIM: To evaluate the clinical profile and effectiveness/safety of patients taking rivaroxaban in clinical practice. METHODS: Retrospective study that included patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke between January 2012 and December 2016 in a tertiary hospital in Spain. RESULTS: A total of 142 patients (median age 78 years, 40.1% men, 32.4% creatinine clearance <50 ml/min; 96...
May 2018: Future Cardiology
David Brun Guinda, Óscar Callen García, Jorge Ondiviela Pérez, María Gracia Aznarez, Pilar Artero Bello, Elena Rivero Fernandez, Adolfo Marquina Barcos, Maite Villarroel Salcedo
AIM: To analyze clinical profile and management of patients with nonvalvular atrial fibrillation treated with rivaroxaban in clinical practice according to age and to ascertain rates of thromboembolic and bleeding events during rivaroxaban therapy. METHODS: Retrospective study of nonvalvular atrial fibrillation patients that started rivaroxaban therapy between May 2013 and February 2017 in the cardiology department of two hospitals from Huesca, Spain. RESULTS: A total of 137 patients (mean age 78...
May 2018: Future Cardiology
Yesenia Pimentel Quezada, Juan Luis Bonilla Palomas, Antonio Luis Gámez López, Mirian Moreno Conde, María Cristina López Ibáñez, Ángel Gallego de la Sacristana López-Serrano
AIM: To analyze the evolution of clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban. METHODS: Retrospective study in which patients treated with rivaroxaban were divided into two groups according to the data in which the initial prescription was performed (November 2012-December 2013 and January 2014-January 2017). RESULTS: 211 patients (mean age 76.7 ± 9.2 years; CHA2 DS2 -VASc 3.8 ± 1.5; HAS-BLED 2...
May 2018: Future Cardiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"